Optimization From Standalone SMARCA2/4 Degrader Therapeutics to Potent ADC Payloads
Time: 3:00 pm
day: Conference Day One
Details:
- Explore the structure-activity optimization that enhanced potency of the early-stage SMARCA2 dual degrader lead
- Outline key modifications that enabled successful translation from oral drug to conjugated payload
- Discuss platform validation through proof-of-concept studies
